First-in-human trial of HemaXellerate-I in patients with bone marrow suppression

Trial Profile

First-in-human trial of HemaXellerate-I in patients with bone marrow suppression

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs HemaXellerate I (Primary)
  • Indications Bone marrow disorders
  • Focus Adverse reactions; First in man; Proof of concept
  • Most Recent Events

    • 24 Oct 2016 Final clinical data on their first 5 patients published in Regen BioPharma media release.
    • 16 Aug 2016 Updated interim results (n=5) published in a Regen BioPharma Inc media release.
    • 11 May 2016 According to Regen media release, the Company intends to amend its previously submitted Investigational New Drug Application for HemaXellerate in order that Regen may obtain consent from the United States Food and Drug Administration (FDA) to pursue this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top